Business Context and Reporting Period
This Form 8-K Current Report was filed by Black Diamond Therapeutics, Inc. (BDTX) on January 20, 2021, regarding events occurring on January 19, 2021. The Company is a Delaware corporation with its principal executive offices in Cambridge, MA, and its common stock trades on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and executive appointments rather than financial performance.
Material Changes
- Board Appointment: The Board of Directors appointed Dr. Kapil Dhingra as a Class III director, effective January 19, 2021. His term will last until the 2023 annual meeting of stockholders or until earlier death, resignation, or removal.
- Independence Status: The Board determined that Dr. Dhingra is not independent under Nasdaq listing standards due to his existing consulting relationship with the Company.
- Committee Assignments: Dr. Dhingra was not appointed to any Board committees at the time of this filing.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business strategy or risks. It details the compensation and contractual arrangements associated with the new director appointment:
- Director Compensation: Dr. Dhingra will receive compensation as a non-employee director, including an initial equity award, in accordance with the Company's Amended and Restated Non-Employee Director Compensation Policy. He will also enter into a standard indemnification agreement.
- Consulting Agreement: The Company maintains a consulting agreement with KAPital Consulting, LLC (managed by Dr. Dhingra), dated July 1, 2017, and amended January 1, 2020.
- Scope: Services not to exceed eight (8) days per year.
- Compensation: An annual retainer of $50,000, paid in equal quarterly installments.
- Term: Automatically renews for successive one-year periods unless either party provides 90 days' written notice of non-renewal.
Important Facts for Investor Verification
- Verify the specific terms of the initial equity award granted to Dr. Dhingra for Board service, as the exact grant size is not detailed in this filing.
- Confirm the impact of Dr. Dhingra's non-independent status on the composition of Board committees and corporate governance compliance.
- Review the full text of the Consulting Agreement with KAPital Consulting, LLC to understand the scope of services beyond the eight-day annual limit.
- Check subsequent filings for any changes to Dr. Dhingra's committee assignments or independence status.